PT3495380T - Coagonistas de glucagon e glp-1 para o tratamento da obesidade - Google Patents

Coagonistas de glucagon e glp-1 para o tratamento da obesidade

Info

Publication number
PT3495380T
PT3495380T PT181822743T PT18182274T PT3495380T PT 3495380 T PT3495380 T PT 3495380T PT 181822743 T PT181822743 T PT 181822743T PT 18182274 T PT18182274 T PT 18182274T PT 3495380 T PT3495380 T PT 3495380T
Authority
PT
Portugal
Prior art keywords
glp
glucagon
obesity
agonists
treatment
Prior art date
Application number
PT181822743T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of PT3495380T publication Critical patent/PT3495380T/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PT181822743T 2012-12-11 2013-12-10 Coagonistas de glucagon e glp-1 para o tratamento da obesidade PT3495380T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261735823P 2012-12-11 2012-12-11

Publications (1)

Publication Number Publication Date
PT3495380T true PT3495380T (pt) 2022-06-28

Family

ID=50588751

Family Applications (2)

Application Number Title Priority Date Filing Date
PT181822743T PT3495380T (pt) 2012-12-11 2013-12-10 Coagonistas de glucagon e glp-1 para o tratamento da obesidade
PT13849992T PT2931745T (pt) 2012-12-11 2013-12-10 Agonistas de glucagon/glp-1 para o tratamento de obesidade

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT13849992T PT2931745T (pt) 2012-12-11 2013-12-10 Agonistas de glucagon/glp-1 para o tratamento de obesidade

Country Status (26)

Country Link
US (4) US9765130B2 (cg-RX-API-DMAC7.html)
EP (2) EP2931745B1 (cg-RX-API-DMAC7.html)
JP (1) JP6490011B2 (cg-RX-API-DMAC7.html)
KR (1) KR102080366B1 (cg-RX-API-DMAC7.html)
CN (2) CN104822699B (cg-RX-API-DMAC7.html)
AR (1) AR093903A1 (cg-RX-API-DMAC7.html)
AU (3) AU2013356934C1 (cg-RX-API-DMAC7.html)
BR (1) BR112015012238B1 (cg-RX-API-DMAC7.html)
CA (1) CA2893445C (cg-RX-API-DMAC7.html)
CY (2) CY1121114T1 (cg-RX-API-DMAC7.html)
DK (2) DK2931745T3 (cg-RX-API-DMAC7.html)
ES (2) ES2698329T3 (cg-RX-API-DMAC7.html)
HR (2) HRP20220734T1 (cg-RX-API-DMAC7.html)
HU (1) HUE039952T2 (cg-RX-API-DMAC7.html)
LT (2) LT3495380T (cg-RX-API-DMAC7.html)
MX (2) MX365458B (cg-RX-API-DMAC7.html)
PL (2) PL2931745T3 (cg-RX-API-DMAC7.html)
PT (2) PT3495380T (cg-RX-API-DMAC7.html)
RS (2) RS63305B1 (cg-RX-API-DMAC7.html)
RU (2) RU2018137842A (cg-RX-API-DMAC7.html)
SG (2) SG11201503230XA (cg-RX-API-DMAC7.html)
SI (2) SI3495380T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201800611T1 (cg-RX-API-DMAC7.html)
TR (1) TR201815172T4 (cg-RX-API-DMAC7.html)
TW (2) TWI617574B (cg-RX-API-DMAC7.html)
WO (1) WO2014091316A2 (cg-RX-API-DMAC7.html)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CA2902352A1 (en) * 2013-03-14 2014-09-18 Medimmune Limited Pegylated glucagon and glp-1 co-agonists for the treatment of obesity
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
CN106519015B (zh) * 2014-09-23 2020-04-17 深圳市图微安创科技开发有限公司 胃泌酸调节素类似物
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
CN117106085A (zh) * 2015-12-23 2023-11-24 美国安进公司 使用gipr结合蛋白与glp-1激动剂的组合来治疗或改善代谢病症的方法
CN106938050B (zh) * 2015-12-29 2021-08-24 派格生物医药(苏州)股份有限公司 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途
SG10202109721PA (en) * 2016-03-10 2021-10-28 Medimmune Ltd Glucagon and glp-1 co-agonists for the treatment of obesity
US20190388510A1 (en) * 2016-06-02 2019-12-26 Indiana University Research And Technology Corporation Glucagon-t3 conjugates
CN107281471A (zh) * 2017-06-26 2017-10-24 中国药科大学 一种改构的胰高血糖素样肽-1及其修饰物的应用
US11419918B2 (en) * 2017-11-06 2022-08-23 Shenzhen Turier Biotech Co., Ltd. Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide
TWI770085B (zh) * 2017-11-21 2022-07-11 日商武田藥品工業股份有限公司 胜肽化合物
SMT202200352T1 (it) 2018-04-05 2022-09-14 Sun Pharmaceutical Ind Ltd Analoghi del glp-1 innovativi
US12257287B2 (en) 2018-11-12 2025-03-25 Tianjin Institute Of Pharmaceutical Research Co., Ltd. Glucagon-derived peptide and use thereof
CA3139613A1 (en) 2019-05-21 2020-11-26 Medimmune Limited Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides
MX2021015930A (es) 2019-07-01 2022-02-03 Medimmune Ltd Composiciones farmaceuticas para peptidos co-agonistas de glucagon y glp-1.
CN112898406B (zh) * 2019-10-12 2023-11-10 深圳纳福生物医药有限公司 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用
EP4069720A4 (en) * 2019-12-03 2023-12-27 MedImmune, LLC COMBINATION THERAPY WITH GLUCAGON AND GLP-1 CO-AGONISTS FOR THE TREATMENT OF OBESITY
TW202140061A (zh) 2020-01-10 2021-11-01 英商梅迪繆思有限公司 用於治療2型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及glp-1協同促效劑
CN113493503B (zh) * 2020-04-08 2022-08-05 浙江道尔生物科技有限公司 一种肠促胰岛素类似物及其制备方法和用途
CN120737188A (zh) 2020-04-24 2025-10-03 勃林格殷格翰国际有限公司 作为长效glp-1/升糖素受体激动剂以治疗脂肪肝疾病及脂肪肝炎的升糖素类似物
TW202313974A (zh) 2021-06-08 2023-04-01 瑞典商阿斯特捷利康公司 用於治療肝病之組合療法
KR20240043778A (ko) 2021-07-30 2024-04-03 베링거 인겔하임 인터내셔날 게엠베하 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법
TW202346323A (zh) 2022-02-07 2023-12-01 英商梅迪繆思有限公司 具有改善的生物穩定性的glp—1及升糖素雙重激動肽
US20240148833A1 (en) * 2022-11-03 2024-05-09 EFIL BioScience Inc. Composition comprising glp-1 receptor agonist and acat inhibitor
WO2024123812A1 (en) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Fusion proteins for the treatment of cardiometabolic diseases
WO2024165571A2 (en) 2023-02-06 2024-08-15 E-Therapeutics Plc Inhibitors of expression and/or function
CN115975057B (zh) * 2023-03-16 2023-05-16 杭州信海医药科技有限公司 一种可妥度肽的固相合成方法
EP4724472A2 (en) 2023-06-09 2026-04-15 Sun Pharmaceutical Industries Limited Glp-1/gip dual, glp-1/gcg dual and glp-1/gip/gcg triple receptor agonists
WO2025024788A1 (en) * 2023-07-27 2025-01-30 Biomedit, Llc Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof
WO2025125576A2 (en) 2023-12-15 2025-06-19 E-Therapeutics Plc Inhibitors of expression and/or function
AU2024408289A1 (en) 2023-12-22 2026-08-06 Tangram Therapeutics Plc Inhibitors of expression and/or function
EP4686757A1 (en) 2024-07-31 2026-02-04 e-therapeutics PLC Inhibitors of expression and/or function
WO2025196502A1 (en) 2024-03-20 2025-09-25 North Carolina Agricultural & Technical State University Choline kinase inhibitors as a therapeutic treatment for obesity
US20260091086A1 (en) 2024-05-20 2026-04-02 Medimmune Limited Polypeptide combinations and uses thereof
CN118787658B (zh) * 2024-06-14 2025-01-21 中国农业大学 一种胰高血糖素样肽-1受体特异性核酸适配体在代谢疾病干预中的应用
WO2026058194A1 (en) 2024-09-12 2026-03-19 Medimmune Limited Polypeptide dosage regimens
WO2026093970A1 (en) 2024-11-01 2026-05-07 Medimmune Limited Combination dosage regimens of amylin receptor agonists and glp-1 receptor agonists

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30326A (en) * 1860-10-09 Steam-g-eneratob
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
EP0401384B1 (en) 1988-12-22 1996-03-13 Kirin-Amgen, Inc. Chemically modified granulocyte colony stimulating factor
CA2497794A1 (en) * 2002-09-06 2004-03-18 Bayer Pharmaceuticals Corporation Modified glp-1 receptor agonists and their pharmacological methods of use
CN1938334A (zh) * 2004-01-30 2007-03-28 瓦拉塔药品公司 Glp-1激动剂和胃泌素化合物的联合使用
DE102004043153B4 (de) * 2004-09-03 2013-11-21 Philipps-Universität Marburg Erfindung betreffend GLP-1 und Exendin
MX2008002028A (es) * 2005-08-11 2008-03-27 Amylin Pharmaceuticals Inc Polipeptidos hibridos con propiedades de seleccion.
CN1935846A (zh) * 2005-09-14 2007-03-28 王庆华 一种用于治疗糖尿病的融合蛋白及其制备方法和应用
US8563521B2 (en) 2007-06-21 2013-10-22 Technische Universitat Munchen Biological active proteins having increased in vivo and/or in vitro stability
WO2009058734A1 (en) * 2007-10-30 2009-05-07 Indiana University Research And Technology Corporation Compounds exhibiting glucagon antagonist and glp-1 agonist activity
WO2010148089A1 (en) 2009-06-16 2010-12-23 Indiana University Research And Technology Corporation Gip receptor-active glucagon compounds
ES2661228T3 (es) * 2010-05-13 2018-03-28 Indiana University Research And Technology Corporation Péptidos de la superfamilia de glucagón que muestran actividad de receptor nuclear de hormona
TWI617574B (zh) * 2012-12-11 2018-03-11 梅迪繆思有限公司 用於治療肥胖之升糖素與glp-1共促效劑

Also Published As

Publication number Publication date
PL3495380T3 (pl) 2022-08-01
US11230584B2 (en) 2022-01-25
WO2014091316A2 (en) 2014-06-19
EP3495380A1 (en) 2019-06-12
SG10201801159WA (en) 2018-03-28
HRP20220734T1 (hr) 2022-09-02
TWI617574B (zh) 2018-03-11
SMT201800611T1 (it) 2019-01-11
JP6490011B2 (ja) 2019-03-27
TW201829452A (zh) 2018-08-16
TW201427993A (zh) 2014-07-16
MX2015006568A (es) 2015-08-05
WO2014091316A3 (en) 2014-10-30
LT3495380T (lt) 2022-06-27
AU2017261505A1 (en) 2017-12-07
EP3495380B1 (en) 2022-03-30
BR112015012238B1 (pt) 2022-03-29
KR102080366B1 (ko) 2020-02-21
AU2017261505B2 (en) 2019-10-10
JP2016501256A (ja) 2016-01-18
CN109776670A (zh) 2019-05-21
AU2019272054A1 (en) 2020-01-02
US20220098265A1 (en) 2022-03-31
US20170342121A1 (en) 2017-11-30
BR112015012238A2 (cg-RX-API-DMAC7.html) 2017-08-15
MX365458B (es) 2019-06-04
RU2018137842A3 (cg-RX-API-DMAC7.html) 2022-04-01
TR201815172T4 (tr) 2018-11-21
MX2019006260A (es) 2019-08-14
HK1216179A1 (en) 2016-10-21
CA2893445A1 (en) 2014-06-19
SI2931745T1 (sl) 2018-11-30
CY1125302T1 (el) 2025-03-28
PL2931745T3 (pl) 2019-04-30
SMT202200266T1 (it) 2022-07-21
AU2013356934A1 (en) 2015-05-21
US9765130B2 (en) 2017-09-19
US20150307579A1 (en) 2015-10-29
ES2926713T3 (es) 2022-10-27
RU2018137842A (ru) 2018-12-13
RU2671088C2 (ru) 2018-10-29
EP2931745B1 (en) 2018-08-22
SG11201503230XA (en) 2015-06-29
RU2015127780A (ru) 2017-01-19
TWI674270B (zh) 2019-10-11
LT2931745T (lt) 2018-11-12
AU2013356934B2 (en) 2017-08-17
KR20150093167A (ko) 2015-08-17
CA2893445C (en) 2020-06-02
HRP20181678T1 (hr) 2019-03-08
MX388904B (es) 2025-03-20
PT2931745T (pt) 2018-11-29
ES2698329T3 (es) 2019-02-04
EP2931745A2 (en) 2015-10-21
AU2017261505C1 (en) 2020-07-30
RS57899B1 (sr) 2019-01-31
AU2013356934C1 (en) 2018-07-05
CY1121114T1 (el) 2019-12-11
DK3495380T3 (da) 2022-06-20
US20200115431A1 (en) 2020-04-16
CN104822699A (zh) 2015-08-05
RS63305B1 (sr) 2022-07-29
AR093903A1 (es) 2015-06-24
DK2931745T3 (en) 2018-12-10
SI3495380T1 (sl) 2022-08-31
CN104822699B (zh) 2019-03-01
HUE039952T2 (hu) 2019-02-28
US10556939B2 (en) 2020-02-11

Similar Documents

Publication Publication Date Title
SMT202200266T1 (it) Co-agonisti di glucagone e glp-1 per il trattamento dell'obesità
ZA201309626B (en) Glucagon/glp-1 reeptor co-agonists
ZA201806637B (en) Glucagon and glp-1 co-agonists for the treatment of obesity
EP2739144A4 (en) COMPOUNDS AND ITS THERAPEUTIC USE
PT3021838T (pt) Tratamento para a obesidade
ZA201502290B (en) 2-phenyl-5-heterocyclyl-tetrahydro-2h-pyran-3-amine compounds for use in the treatment of diabetes and ist associated disorders
EP2867239A4 (en) OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES FOR THE TREATMENT OF DIABETES
SG11201509782TA (en) Compositions and methods for the treatment of diabetes and pre-diabetes
SI2900230T1 (sl) Sestavki za zdravljenje debelosti in postopki njihove uporabe
ZA201501503B (en) Bio-inoculant and use thereof for treatment of effluents
IL238126A0 (en) Compositions for the treatment and prevention of obesity
PL3074033T3 (pl) Związki do leczenia otyłości i sposoby ich zastosowania
ZA201408065B (en) Compositions and methods for the treatment of diabetes
IL235066A0 (en) Sorcs1 for use in the treatment of obesity and overweight
ZA201404738B (en) Treatment of type i and type ii diabetes
ZA201203013B (en) Fracture reduction apparatus